Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

[Pharmacologic treatment of osteoporosis--2011].

Lakatos P.

Orv Hetil. 2011 Aug 14;152(33):1320-6. doi: 10.1556/OH.2011.29111. Review. Hungarian.

PMID:
21824859
2.

New developments in the treatment of osteoporosis.

Eriksen EF, Halse J, Moen MH.

Acta Obstet Gynecol Scand. 2013 Jun;92(6):620-36. doi: 10.1111/j.1600-0412.2012.01473.x. Review.

PMID:
22646526
3.

Management of postmenopausal osteoporosis and the prevention of fractures.

Gambacciani M, Levancini M.

Panminerva Med. 2014 Jun;56(2):115-31. Epub 2014 Jun 19.

4.
5.
6.

Osteoporosis: non-hormonal treatment.

Rizzoli R.

Climacteric. 2007 Oct;10 Suppl 2:74-8.

PMID:
17882678
7.

[Osteoporosis].

Uelbelhart B, Rizzoli R.

Rev Med Suisse. 2012 Jan 18;8(324):109-10, 112-5. French.

PMID:
23185820
8.

Developments in the pharmacotherapeutic management of osteoporosis.

Close P, Neuprez A, Reginster JY.

Expert Opin Pharmacother. 2006 Aug;7(12):1603-15. Review.

PMID:
16872263
9.

[Osteoporosis].

Buck G, Perger L, Bischoff-Ferrari HA.

Praxis (Bern 1994). 2011 Jul 6;100(14):821-32. doi: 10.1024/1661-8157/a000599. German. No abstract available.

PMID:
21732293
10.

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.

Wensel TM, Iranikhah MM, Wilborn TW.

Pharmacotherapy. 2011 May;31(5):510-23. doi: 10.1592/phco.31.5.510. Review.

PMID:
21923432
11.

Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review.

Gallacher SJ, Dixon T.

Calcif Tissue Int. 2010 Dec;87(6):469-84. doi: 10.1007/s00223-010-9420-x. Epub 2010 Sep 26. Review.

PMID:
20872215
12.

Efficacy, effectiveness and side effects of medications used to prevent fractures.

Reid IR.

J Intern Med. 2015 Jun;277(6):690-706. doi: 10.1111/joim.12339. Erratum in: J Intern Med. 2015 Sep;278(3):333.

13.

Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.

Josse R, Khan A, Ngui D, Shapiro M.

Curr Med Res Opin. 2013 Mar;29(3):205-16. doi: 10.1185/03007995.2013.763779. Epub 2013 Jan 25. Review. Erratum in: Curr Med Res Opin. 2013 Sep;29(9):1211.

PMID:
23297819
14.

The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden.

Murphy DR, Smolen LJ, Klein TM, Klein RW.

BMC Musculoskelet Disord. 2012 Oct 30;13:213. doi: 10.1186/1471-2474-13-213.

15.

Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.

Ström O, Jönsson B, Kanis JA.

Osteoporos Int. 2013 Apr;24(4):1491-502. doi: 10.1007/s00198-012-2115-6. Epub 2012 Dec 7.

PMID:
23224141
16.

Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis.

Lewiecki EM.

J Womens Health (Larchmt). 2009 Oct;18(10):1615-26. doi: 10.1089/jwh.2008.1086. Review.

PMID:
19857095
17.

[Denosumab--a new efficient osteoporosis therapy].

Rejnmark L, Vestergaard P, Mosekilde L.

Ugeskr Laeger. 2011 Jan 31;173(5):346-9. Danish.

PMID:
21276398
18.

What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis?

Miller PD, Derman RJ.

Osteoporos Int. 2010 Nov;21(11):1793-802. doi: 10.1007/s00198-010-1208-3. Epub 2010 Mar 23. Review.

PMID:
20309524
19.

Comparing clinical and economic outcomes of biologic and conventional medications in postmenopausal women with osteoporosis.

Hernandez I, Zhang Y.

J Eval Clin Pract. 2015 Oct;21(5):840-7. doi: 10.1111/jep.12389. Epub 2015 Jun 9.

PMID:
26059485
20.

Prevention and treatment of postmenopausal osteoporosis.

Tella SH, Gallagher JC.

J Steroid Biochem Mol Biol. 2014 Jul;142:155-70. doi: 10.1016/j.jsbmb.2013.09.008. Epub 2013 Oct 29. Review.

Supplemental Content

Support Center